<DOC>
	<DOC>NCT01339182</DOC>
	<brief_summary>This study is aimed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics of a single-dose of Pegylated-Somatropin in healthy male volunteers, and collect scientific data for the design and conduct of subsequent studies.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects Age(yr)between 18 and 45 Body mass index(BMI)between 20 and 28 sign informed consent Known hypersensitivity to somatropin or any other components of the study drug Organic lesion in heart, liver, kidney or any other major organs History of diabetes mellitus, cancer, autoimmune disease, genetic disease, mental disease Alcoholic, smokers or drug abusers Blood donation, or massive blood loss due to injury or surgery within 3 months Other conditions which in the opinion of the investigator preclude enrollment into the study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>somatropin</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>male</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>safety</keyword>
</DOC>